Moderna Is Being Sued For Possibly Violating Securities Regulations And Shareholders Are Invited To Participate
Moderna (NASDAQ:MRNA) is facing a class action lawsuit for alleged violations of securities regulations. The Schall Law Firm has announced a reminder to investors who purchased Moderna securities between January 18, 2023, and June 25, 2024, to join the lawsuit before October 8, 2024.
The lawsuit claims Moderna made false and misleading statements about its mRESVIA (mRNA-1345) product, overstating its effectiveness and commercial prospects. When the truth was revealed, investors reportedly suffered damages.
Shareholders who experienced losses are encouraged to contact the Schall Law Firm to discuss their rights. The class has not yet been certified, and interested parties can choose to participate or remain absent class members.
Moderna (NASDAQ:MRNA) sta affrontando una causa collettiva per presunti violazioni delle normative sui titoli. Lo Studio Legale Schall ha annunciato un promemoria per gli investitori che hanno acquistato titoli di Moderna tra il 18 gennaio 2023 e il 25 giugno 2024, per unirsi alla causa prima del 8 ottobre 2024.
La causa sostiene che Moderna ha fatto dichiarazioni false e ingannevoli sul suo prodotto mRESVIA (mRNA-1345), esagerando la sua efficacia e le prospettive commerciali. Quando la verità è stata rivelata, gli investitori hanno subito danni.
Gli azionisti che hanno subito perdite sono incoraggiati a contattare lo Studio Legale Schall per discutere dei loro diritti. La classe non è ancora stata certificata e le parti interessate possono scegliere di partecipare o rimanere membri assenti della classe.
Moderna (NASDAQ:MRNA) enfrenta una demanda colectiva por supuestas violaciones de las regulaciones de valores. El bufete de abogados Schall ha anunciado un recordatorio para los inversores que compraron valores de Moderna entre el 18 de enero de 2023 y el 25 de junio de 2024, para unirse a la demanda antes del 8 de octubre de 2024.
La demanda sostiene que Moderna hizo declaraciones falsas y engañosas sobre su producto mRESVIA (mRNA-1345), exagerando su efectividad y perspectivas comerciales. Cuando se reveló la verdad, los inversores supuestamente sufrieron pérdidas.
Se anima a los accionistas que experimentaron pérdidas a ponerse en contacto con el bufete de abogados Schall para discutir sus derechos. La clase aún no ha sido certificada, y las partes interesadas pueden optar por participar o permanecer como miembros ausentes de la clase.
모더나 (NASDAQ:MRNA)는 증권 규정 위반 혐의로 집단 소송에 직면해 있습니다. Schall 법무법인은 2023년 1월 18일부터 2024년 6월 25일 사이에 모더나 증권을 구매한 투자자들에게 2024년 10월 8일 이전 소송에 참여할 것을 알리는 리마인더를 발표했습니다.
소송은 모더나가 mRESVIA(mRNA-1345) 제품에 대해 허위 및 오해의 소지가 있는 진술을 했고, 그 효과성과 상업적 전망을 과장했다고 주장합니다. 진실이 드러났을 때, 투자자들은 손해를 입었다고 전해지고 있습니다.
손실을 경험한 주주들은 자신의 권리에 대해 논의하기 위해 Schall 법무법인에 연락할 것을 권장합니다. 클래스는 아직 인증되지 않았으며, 이해관계자는 참여하거나 클래스의 비참여자로 남을 수 있습니다.
Moderna (NASDAQ:MRNA) fait face à un recours collectif pour des violations présumées des réglementations sur les valeurs mobilières. Le cabinet d'avocats Schall a annoncé un rappel aux investisseurs ayant acheté des titres de Moderna entre le 18 janvier 2023 et le 25 juin 2024, pour se joindre au procès avant le 8 octobre 2024.
Le recours allègue que Moderna a fait des déclarations fausses et trompeuses concernant son produit mRESVIA (mRNA-1345), exagérant son efficacité et ses perspectives commerciales. Lorsque la vérité a été révélée, les investisseurs auraient subi des pertes.
Les actionnaires ayant subi des pertes sont encouragés à contacter le cabinet d'avocats Schall pour discuter de leurs droits. La classe n’a pas encore été certifiée et les parties intéressées peuvent choisir de participer ou de rester membres absents de la classe.
Moderna (NASDAQ:MRNA) sieht sich einer Sammelklage wegen angeblicher Verstöße gegen Wertpapiergesetze gegenüber. Die Schall Anwaltskanzlei hat Anleger, die zwischen dem 18. Januar 2023 und dem 25. Juni 2024 Moderna-Wertpapiere erworben haben, daran erinnert, sich vor dem 8. Oktober 2024 der Klage anzuschließen.
In der Klage wird behauptet, dass Moderna falsche und irreführende Angaben zu seinem Produkt mRESVIA (mRNA-1345) gemacht hat und die Wirksamkeit sowie die kommerziellen Perspektiven übertrieben hat. Als die Wahrheit ans Licht kam, erlitten die Investoren angeblich Schäden.
Aktionäre, die Verluste erlitten haben, werden ermutigt, die Schall Anwaltskanzlei zu kontaktieren, um ihre Rechte zu besprechen. Die Klasse wurde noch nicht zertifiziert und interessierte Parteien können entscheiden, ob sie teilnehmen oder als passive Klassenmitglieder bleiben wollen.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Moderna's mRESVIA (mRNA-1345) was less effective that it had portrayed to the market. The commercial prospects of mRNA-1345 were overstated. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Moderna, investors suffered damages.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
What is the deadline for Moderna shareholders to join the class action lawsuit?
What period does the Moderna class action lawsuit cover?
What are the main allegations against Moderna in the lawsuit?
Who is representing the shareholders in the Moderna lawsuit?
What should Moderna shareholders do if they want to participate in the lawsuit?
